Clinical Trials

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06448754 2026-04-13

eVOLVE-01

180 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07221474 2026-04-13

INTerpath-13

180 enrolled

Phase 3 Not yet recruiting

Squamous Non-small Cell Lung Cancer

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

494 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT07063745 2026-04-07

MountainTAP-29

Phase 2/3 Recruiting

590 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Lung Neoplasms

NCT07216105 2026-04-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Phase 1 Recruiting

113 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

350 enrolled

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT06422143 2026-04-02

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Phase 3 Recruiting

851 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04205812 2026-03-31

POD1UM-304

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06692738 2026-03-31

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3 Recruiting

880 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06788912 2026-03-31

MK-3475-01E

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT04736173 2026-03-30

ARC-10

169 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06996782 2026-03-30

ALTAIR

Phase 1/2 Recruiting

152 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

453 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

756 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05633667 2026-03-17

VELOCITY-Lung

270 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05984277 2026-03-17

eVOLVE-Lung02

1,200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04165070 2026-03-16

MK-3475-01A

Phase 1/2 Recruiting

450 enrolled

Phase 1/2 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

596 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT07465757 2026-03-12

ALISCA-Lung2

Phase 2 Not yet recruiting

50 enrolled

Small Cell Lung Carcinoma

NCT04832854 2026-03-11

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 2 Terminated

50 enrolled 18 charts

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05904379 2026-03-09

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

233 enrolled

Advanced Non-small-cell Lung Cancer

NCT06194448 2026-03-06

NEOLA

76 enrolled

Lung Neoplasms

NCT06693336 2026-03-06

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

42 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05247684 2026-03-05

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

90 enrolled

Phase 1 Active not recruiting

Resectable Non-small Cell Lung Cancer

NCT06883630 2026-03-05

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

121 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT03631199 2026-02-25

CANOPY-1

Phase 3 Terminated

673 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 2 FDA

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04644068 2026-02-19

PETRA

702 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06731907 2026-02-18

MK-3475-01G

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05775289 2026-02-11

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

182 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung

NCT05577702 2026-02-09

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Phase 2 Completed

121 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT05226598 2026-02-05

MK-7684A-007

Phase 3 Completed

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05502237 2026-01-30

STAR-121

1,021 enrolled